Mesoblast Balance Sheet
NASDAQ: MESOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Mesoblast financial position
At the end of fiscal 2025, Mesoblast reported total assets of $784.7 million, up 17.3% from a year earlier against total liabilities of $187.2 million. Shareholders' equity stood at $597.4 million, or 76.1% of assets. The company held $161.6 million in cash and equivalents against $176.0 million of debt, a net debt position of $14.5 million.
The current ratio (current assets divided by current liabilities) was 1.99, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.29.
Summary generated from market data by MetaCap's automated system. Methodology
Mesoblast balance sheet (annual)
| Fiscal year (USD) | FY 20252025-06-30 | FY 20242024-06-30 | FY 20232023-06-30 | FY 20222022-06-30 | FY 20212021-06-30 | FY 20202020-06-30 | FY 20192019-06-30 | FY 20182018-06-30 | FY 20172017-06-30 | FY 20162016-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 161.55M | 62.96M | 71.32M | 60.45M | 136.88M | 129.33M | 50.43M | 37.76M | 45.76M | 80.94M |
| Receivables | 14.87M | 20.95M | 7.00M | 4.40M | 4.84M | 1.57M | 4.06M | 50.37M | 3.74M | — |
| Inventory | 22.25M | 0 | — | — | — | — | — | — | — | — |
| Total Current Assets | 204.35M | 86.46M | 81.66M | 69.84M | 148.23M | 136.55M | 62.52M | 101.07M | 63.61M | — |
| Property, Plant & Equipment | 1.70M | 1.11M | 1.36M | 2.04M | 3.02M | 2.29M | 826.00K | 1.08M | 1.81M | 3.06M |
| Total Assets | 784.68M | 669.15M | 669.41M | 662.14M | 744.72M | 733.60M | 652.12M | 692.44M | 655.69M | — |
| Accounts Payable | 19.08M | 7.07M | 20.14M | 23.08M | 19.60M | 24.97M | 13.06M | 18.92M | 21.80M | — |
| Short-Term Debt | 108.31M | 27.72M | 11.90M | 10.03M | 106.40M | 64.91M | 28.01M | — | — | — |
| Total Current Liabilities | 102.63M | 73.24M | 41.98M | 51.37M | 94.27M | 90.14M | 44.33M | 24.00M | 36.67M | — |
| Long-Term Debt | 67.74M | 100.48M | 102.81M | 91.62M | 41.05M | 57.02M | 67.28M | 59.40M | — | — |
| Total Liabilities | 187.24M | 188.80M | 167.58M | 165.10M | 163.32M | 184.28M | 171.06M | 146.44M | 138.92M | — |
| Shareholders' Equity | 597.44M | 480.36M | 501.84M | 497.04M | 581.40M | 549.33M | 481.05M | 546.01M | 516.77M | 528.16M |
| Retained Earnings | -1.01B | -908.76M | -820.80M | -738.92M | -647.57M | -548.76M | -469.99M | -380.19M | -344.90M | — |
| Total Debt | 176.05M | 128.21M | 114.72M | 101.65M | 147.44M | 121.93M | 95.29M | 59.40M | — | — |
| Net Cash (Debt) | -14.50M | -65.25M | -43.40M | -41.20M | -10.56M | 7.39M | -44.87M | -21.63M | 45.76M | 80.94M |
This table shows 10 annual periods of Mesoblast's balance sheet, from FY 2025 back to FY 2016, across 15 line items including cash & equivalents, receivables, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow MESO's reporting calendar. What is a balance sheet?